Optiscan Accelerates Head and Neck Cancer Clinical Trial to Live Surgical Imaging Phase Ahead of Schedule

Overview of Optiscan Imaging and Its Core Technology Platforms

Optiscan Imaging Ltd is an Australian medical device company based at 16 Miles Street, Mulgrave, Victoria. The company develops cutting-edge imaging technologies aimed at precision surgery and digital pathology. Its flagship platforms include InVue™, designed for real-time intraoperative imaging during surgeries, and InForm™, a digital pathology platform for specimen analysis. Both platforms utilize real-time microscopic visualization to aid clinicians in tissue assessment and surgical decision-making. Optiscan is advancing these technologies through multiple clinical trials and regulatory pathways, focusing primarily on oncology applications such as head and neck cancer.

The InVue™ platform enables surgeons to visualize tissue microscopically during live surgery, enhancing precision. The InForm™ platform complements this by providing digital pathology analysis for fresh, fixed, and in vivo tissue samples. Both systems are designed to integrate seamlessly into existing surgical and pathology workflows, as demonstrated in recent clinical trial experiences. Optiscan’s commercial strategy involves validating these platforms across diverse tissue types, procedures, and healthcare environments to drive adoption in oncology and surgical applications.

Strong Stage 1 Results Propel Early Transition to Live Surgical Imaging

Optiscan’s transition from Stage 1 to Stage 2 of the head and neck cancer study occurred ahead of schedule due to strong early-phase results. Initiated in late 2025 and announced on 3 December 2025, Stage 1 focused on ex vivo imaging of head and neck cancer tissues. The initial 10 cases produced imaging data with sufficient rate, quality, and tissue diversity to secure Ethics Committee approval for Stage 2. The high-quality images, which aligned closely with standard histopathology findings as noted by the lead investigator, provided the clinical justification for advancing. This accelerated timeline validates the effective integration of InVue™ and InForm™ platforms into clinical workflows at the research site.

Lead investigator and head and neck cancer surgeon Dr Chady Sader highlighted encouraging recruitment rates and imaging quality, emphasizing the technology’s potential in surgical environments. The Ethics Committee’s approval for Stage 2 was based on these positive outcomes from Stage 1. Optiscan noted that this early progression delivers both time and cost efficiencies, though specific acceleration metrics and cost savings were not disclosed.

Stage 2 Study Design and Objectives for In Vivo Surgical Imaging

Stage 2 marks a significant escalation, shifting from ex vivo tissue imaging to live intraoperative imaging during head and neck cancer surgeries. The protocol focuses on capturing in vivo images with the Optiscan InVue™ device during surgery, supplemented by ex vivo imaging of tissue samples using the InForm™ device. Sodium fluorescein is employed as the contrast agent with InVue™, leveraging collaborations with Australian Clinical Labs and Long Grove Pharmaceuticals. This dual approach allows correlation of real-time surgical imaging with detailed pathology analysis.

The trial is conducted at St John of God Murdoch Hospital in Perth, in collaboration with Australian Clinical Labs, which supports pathology specimen analysis via the InForm™ platform. Dr Sader leads the study and has recruited the initial patient cohort. The design aims to assess how real-time microscopic imaging can assist surgeons in evaluating tissue structures and surgical margins during complex head and neck cancer operations. Stage 2 will also expand the range of tissue types imaged compared to Stage 1.

FDA Regulatory Evidence Generation and Approval Strategy

A primary goal of the head and neck study is to generate regulatory evidence supporting Optiscan’s planned US FDA submissions. The imaging and pathology data collected will underpin submissions demonstrating the broad applicability of Optiscan’s platform technology. By producing paired imaging and pathology evidence across fresh, fixed, and in vivo tissues, the study strengthens the regulatory dataset and informs future US clinical trial designs. Validating the technology in complex surgical oncology settings also supports workflow integration discussions with US regulators.

Data from this and multiple studies will be consolidated to showcase the InVue™ and InForm™ platforms’ versatility across various tissue types and clinical scenarios. Figure 3 in the company’s announcement outlines FDA milestone progress for both devices, though specific timelines remain undisclosed. This study is a critical step in validating the technology for clinical use, emphasizing the generation of comprehensive evidence across multiple tissue preparations and imaging modalities. The FDA pathway is a key component of Optiscan’s broader regulatory plan, with submission timelines yet to be detailed.

Advancing Oral Cancer AI Imaging Algorithm with Study Data

In addition to clinical validation, the head and neck cancer study supports development of Optiscan’s oral cancer artificial intelligence imaging algorithm. Imaging data from both Stage 1 and Stage 2 will feed into AI-driven image analysis tools designed for automated tissue assessment. The company confirmed that the study’s imaging and pathology data will enhance the oral cancer AI algorithm, positioning the trial as both a clinical validation and AI development initiative. The high-quality Stage 1 data, showing strong concordance with histopathology, is well-suited for algorithm training.

Optiscan’s CEO Dr Camile Farah stated the study advances multiple strategic priorities, including AI development, future US clinical activities, and regulatory pathways. He emphasized the company’s goal to validate the Optiscan platform across diverse tissues, procedures, and healthcare settings. The AI algorithm represents a long-term value driver by potentially improving clinical utility and adoption of the imaging platforms in surgical and pathology environments.

Collaborations with Australian Clinical Labs and Long Grove Pharmaceuticals

Optiscan’s strategic partnerships directly support the head and neck study and broader platform validation. Australian Clinical Labs provides pathology specimen analysis via the InForm™ platform for fresh and fixed tissues across both study stages. This collaboration, announced on 10 November 2025, integrates digital pathology within the clinical workflow alongside surgical imaging. Long Grove Pharmaceuticals, announced on 23 June 2025, supplies the sodium fluorescein contrast agent used with the InVue™ device. These collaborations enable Optiscan to conduct integrated surgical and pathology studies without full vertical integration of all services.

This partnership framework highlights Optiscan’s strategy to integrate its platforms within existing healthcare infrastructure and supplier networks. Australian Clinical Labs’ ongoing involvement offers both clinical validation and a potential commercial channel, supporting future adoption discussions. Utilizing sodium fluorescein, an established pharmaceutical agent, aligns with regulatory and clinical adoption strategies by leveraging approved contrast media.

Clinical, Regulatory, and Commercial Importance of Stage 2 Advancement

Optiscan’s announcement outlines three key significance areas for Stage 2 progression. Clinically, Stage 2 enables live intraoperative imaging during head and neck cancer surgery, aiding tissue architecture assessment and surgical margin evaluation where real-time decisions are critical. Given the complex anatomy in head and neck surgeries, accurate margin assessment greatly impacts outcomes and prognosis. Real-time visualization could influence intraoperative decisions on resection boundaries. Lead investigator Dr Sader emphasized the technology’s potential to support tissue assessment and margin evaluation.

From a regulatory perspective, the paired imaging and pathology data across fresh, fixed, and in vivo tissues enhances the dataset for FDA submissions and future US trials. This multi-modal evidence generation provides a more comprehensive regulatory package than single-modality data. Commercially, demonstrating workflow integration in complex surgical oncology supports broader adoption of InVue™ and InForm™ platforms across precision surgery, digital pathology, and cancer imaging. Validation in demanding head and neck surgery may establish credibility for use in other surgical specialties and tissue types.

CEO and Lead Investigator Insights on Study Progress

CEO Dr Camile Farah described the early Stage 2 start as indicative of the smooth integration of InVue™ and InForm™ into surgical and pathology workflows, and the strong collaboration with St John of God Murdoch Hospital and Australian Clinical Labs. He noted the study effectively evaluates imaging technologies in head and neck cancer surgery within a real-world clinical setting. Dr Farah highlighted that Stage 1 outcomes position Optiscan to demonstrate how real-time microscopic imaging can assist surgeons with tissue assessment and surgical decisions during complex oncology procedures. He also pointed out that the study delivers benefits beyond clinical development, supporting validation across multiple tissues and contributing to AI, US clinical activities, and regulatory strategies.

Lead investigator Dr Chady Sader expressed optimism about recruitment pace, image quality, and concordance with standard histopathology. He identified the move to live imaging as a crucial step in assessing the technology’s role in assisting surgeons during head and neck cancer operations. Dr Sader’s remarks confirm that InVue™ and InForm™ generate diagnostically relevant data comparable to established pathology methods, reinforcing the clinical importance of the technology in tissue and margin assessment.

Investment Outlook and Upcoming Milestones

Investors following Optiscan should monitor several near- and medium-term developments post-Stage 2 initiation. Key upcoming milestones include generation of in vivo surgical imaging data and publication or disclosure of Stage 2 findings. Successful integration of the InVue™ platform into live surgical workflows and production of clinically meaningful imaging data will be critical validation points. Details on additional patient recruitment and Stage 2 completion timelines were not disclosed. Subsequent Stage 2 results, including intraoperative imaging quality, pathology concordance, and clinical utility assessments, will likely impact investor sentiment regarding regulatory and commercial prospects.

Longer-term considerations include timing and outcomes of FDA submissions, progress of the oral cancer AI algorithm, and evidence of broader platform adoption beyond the initial head and neck study. Optiscan indicated that data from this study will be combined with multiple studies to support FDA submissions, implying parallel clinical evidence generation. The announcement suggests further clinical, regulatory, or commercial updates may follow as the platform advances. The immediate share price impact was not evident from public information.

Clinical Study Context and Real-World Surgical Validation

This head and neck cancer study is the first human clinical trial to image head and neck cancer tissues in vivo during surgery, marking a pioneering application of the InVue™ and InForm™ platforms. Conducted at St John of God Murdoch Hospital, the study evaluates the technology’s practical utility and integration in a complex surgical environment. Head and neck cancer surgery involves intricate anatomy and critical structures, with precise margin assessment essential for patient outcomes, making it an ideal setting for validating real-time imaging technology. Optiscan emphasizes the study’s role in assessing technology performance in a real-world clinical environment beyond laboratory settings.

The involvement of an experienced head and neck cancer surgeon as lead investigator adds clinical credibility to the technology’s assessment and potential surgical impact. Recruiting 10 cases in Stage 1 and advancing to Stage 2 confirms operational feasibility within the hospital. The company notes the ease of integrating both platforms into surgical and pathology workflows, indicating no significant implementation barriers during Stage 1. This real-world validation may be more persuasive to other surgical centers and healthcare systems considering future adoption than lab-based data alone.